Vasopressin and hypercalciuria in enuresis: a reappraisal

What Was Tested

Researchers studied Vasopressin in this controlled clinical trial publication.

To test the hypotheses that vasopressin deficiency or hypercalciuria are important in polyuric and non-polyuric bedwetting, as nocturnal polyuria is a pathogenetic factor in enuresis responsive to antidiuretic therapy with desmopressin.

Who Took Part

The study group was 15 children.

The age groups tagged for this paper are infants, young children, children and teenagers, both men and women.

Vasopressin deficiency has been implicated as a cause of nocturnal polyuria, but measurements of vasopressin in plasma have given contradictory results, because the hormone is released in pulses.

Twenty-eight enuretic children who responded to desmopressin therapy with or without added anticholinergic agents (diuresis-dependent enuresis, DE), 15 children with therapy-resistant enuresis (not diuresis-dependent, NDE) and 51 continent controls were assessed.

How the Study Was Run

A time span of 2 days appears in the methods.

Urinary levels reflect the secretion over longer periods.

Hypercalciuria has also been proposed as a pathogenetic factor.

Urinary vasopressin, calcium and osmolality were measured in the morning after a 12-h thirst provocation.

Urine production was recorded for 2 days.

What Was Measured

The subject headings attached to it are Calcium, Deamino Arginine Vasopressin, Enuresis, Renal Agents and Vasopressins.

What This Means in Plain Language

This is a controlled clinical trial of Vasopressin in 15 children over 2 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2002 (BJU international), a journal based in England.

More context: the Vasopressin compound page, all human trials.